Rituximab (anti-CD20) for Refractory IgG4-RD

Type: drug

Status: FDA Approved (for other conditions, used off-label)

Developer: Genentech/Biogen

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026